In:
Asia-Pacific Journal of Clinical Oncology, Wiley, Vol. 14, No. 2 ( 2018-04)
Abstract:
We aimed to find the optimal route of iron supplementation in patients with malignancy and iron deficiency (true or functional) anemia not receiving erythropoiesis stimulating agents (ESA). Methods Adult patients with malignancy requiring chemotherapy, hemoglobin (Hb) 〈 12 g/dL and serum ferritin 〈 100 mcg/mL, transferrin saturation 〈 20% or hypochromic red blood cells 〉 10% were randomized to intravenous (IV) iron sucrose or oral ferrous sulfate. The primary endpoint was change in Hb from baseline to 6 weeks. Secondary endpoints included blood transfusion, quality of life (QoL), toxicity, response and overall survival. Results A total of 192 patients were enrolled over 5 years: 98 on IV arm and 94 on oral arm. Median age was 51 years; over 95% patients had solid tumors. The mean absolute increase in Hb at 6 weeks was 0.11 g/dL (standard deviation [SD]: 1.48) in IV arm and −0.16 g/dL (SD: 1.36) in oral arm, P = 0.23. Twenty‐three percent patients on IV iron and 18% patients on oral iron had a rise in Hb of ≥1 g/dL at 6 weeks, P = 0.45. Thirteen patients (13.3%) on the IV iron arm and 14 patients (14.9%) on the oral arm required blood transfusion, P = 1.0. Gastrointestinal toxicity (any grade) developed in 41% patients on IV iron and 44% patients on oral iron, P = 1.0. 5 patients on IV iron and none on oral iron had hypersensitivity, P = 0.06. QoL was not significantly different between the two arms. Conclusion IV iron was not superior to oral iron in patients with malignancy on chemotherapy and iron deficiency anemia.
Type of Medium:
Online Resource
ISSN:
1743-7555
,
1743-7563
DOI:
10.1111/ajco.2018.14.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2187409-8
Permalink